REG - Spectral MD Holdings - Changes to Board of Directors

Spectral MD HoldingsAnnouncement

24/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221024:nRSX7805Da&default-theme=true

RNS Number : 7805D  Spectral MD Holdings, Ltd.  24 October 2022

 

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company")

 

Change to Board of Directors

 

LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a
predictive analytics company with proprietary AI algorithms and optical
technology for faster and more accurate treatment decisions in wound care,
announces that Erich Spangenberg, Non-Executive Director, has elected to
resign as a director of the Company effective October 31(st)2022.

Mr. Spangenberg commented: "I was the first outside investor in Spectral MD in
2011 and have served on the Board of Directors for over 10 years. I am the CEO
of two other businesses that are now at a point in their development where
they simply demand all my available business time. Today, my family is the
largest shareholder in Spectral MD and my plan is to continue to support the
Company, management and the Board of Directors. Wensheng is an exceptional CEO
and I strongly believe that under his guidance great things lie ahead for
Spectral MD."

 

Wensheng Fan, Spectral MD Chief Executive Officer, said: "Erich has
consistently brought tremendous insights to our Company through his extensive
experience and broad industry knowledge in technology, finance, IP and
governance. Erich has been, and I am sure will continue to be a strong
supporter of Spectral MD. On behalf of the entire Spectral MD team, I would
like to thank Erich for his commitment and contributions to the Company."

 

Martin Mellish, Chairman of the Board, commented: "On behalf of the Board and
the Company, I would like to thank Erich for his exceptional service on the
Board of Spectral MD over the years as the Company's largest shareholder and
supporter. The Board is finalising its evaluation of the appropriate skill set
and profile of a replacement Non-Executive Director on the Board as we
progress to the next stage of the Company's development, and we look forward
to initiating a selection process."

 

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ('MAR'). Upon the publication of this
announcement via Regulatory Information Service ('RIS'), this inside
information is now considered to be in the public domain.

 

For further information please contact:

 

 Spectral MD Holdings, Ltd.                                                      investors.spectralmd.com
 Wensheng Fan, Chief Executive Officer                                           via Walbrook PR
 Nils Windler, Chief Financial Officer

 SP Angel Corporate Finance LLP (NOMAD and Joint Broker)                         Tel: +44 (0)20 3470 0470
 Stuart Gledhill/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Rob Rees (Sales & Broking)

 Stifel Nicolaus Europe Limited (Joint Broker)                                   Tel: +44 (0)20 7710 7600

 Charles Hoare / Ben Maddison / Nick Harland /

 Will Palmer-Brown

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com
 Paul McManus / Louis Ashe-Jepson                  Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393

 Alice Woodings                                    +44 (0)7407 804 654

 

 

About Spectral MD:
 

We are a dedicated team of forward-thinkers striving to revolutionize the
management of wound care by "Seeing the Unknown" ® with our DeepView(®)
Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAKEFADFAFFA